Johnson & Johnson

JNJ · NYSE

Johnson & Johnson reported FY2025 revenue of $94.2 billion, FY2025 net income of $26.8 billion and 2026 Q1 revenue of $24.1 billion. The thesis depends on pharma growth, medtech execution, litigation outcomes and cash conversion.

Follow Add to Watchlist Ask Question

NYSE JNJ Coverage Bootstrap Johnson & Johnson

Latest ReportMay 19, 2026Johnson & Johnson: the healthcare compounder has to keep litigation from swallowing the pipelineView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.